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Abstract
Introduction Previous epidemiologic studies suggest that
women with variant cytochrome P4501A1 (CYP1A1)
genotypes who smoke cigarettes are at increased risk for breast
cancer.
Methods We evaluated the association of breast cancer with
CYP1A1 polymorphisms and cigarette smoking in a population-
based, case–control study of invasive breast cancer in North
Carolina. The study population consisted of 688 cases (271
African Americans and 417 whites) and 702 controls (285
African Americans and 417 whites). Four polymorphisms in
CYP1A1 were genotyped using PCR/restriction fragment
length polymorphism analysis: M1 (also known as CYP1A1*2A),
M2 (CYP1A1*2C), M3 (CYP1A1*3), and M4 (CYP1A1*4)
Results No associations were observed for CYP1A1 variant
alleles and breast cancer, ignoring smoking. Among women
who smoked for longer than 20 years, a modest positive
association was found among women with one or more M1
alleles (odds ratio [OR] = 2.1, 95% confidence interval [CI] =
1.2–3.5) but not among women with non-M1 alleles (OR = 1.2,
95% CI = 0.9–1.6). Odds ratios for smoking longer than 20
years were higher among African-American women with one or
more M3 alleles (OR = 2.5, 95% CI = 0.9–7.1) compared with
women with non-M3 alleles (OR = 1.3, 95% CI = 0.8–2.2). ORs
for smoking in white women did not differ appreciably based
upon M2 or M4 genotypes.
Conclusions Cigarette smoking increases breast cancer risk in
women with CYP1A1 M1 variant genotypes and in African-
American women with CYP1A1 M3 variant genotypes, but the
modifying effects of the CYP1A1 genotype are quite weak.
Keywords: African Americans, breast cancer, cytochrome P4501A1
Introduction
Cigarette smoking is a major route of exposure to many
potential human carcinogens. Cigarette smoking has been
associated with increased risk of breast cancer in some
epidemiologic studies, but many studies showed no effect
or an inverse association [1,2]. The most consistent finding
appears to be a weak positive association following a long
duration of smoking [3]. In an attempt to resolve these
inconsistencies, recent epidemiologic studies have
focused on interactions between cigarette smoking and
genetic factors involved in the metabolism of tobacco-
related carcinogens [4]. If interactions are observed
between smoking and genes involved in the metabolism of
specific compounds, a stronger case can be made that
associations between smoking and breast cancer are
causal and not due entirely to chance or to bias.
The cytochrome P4501A1 (CYP1A1) gene encodes an
enzyme with aryl hydrocarbon hydroxylase activity. Forma-
tion of aryl epoxides by aryl hydrocarbon hydroxylase is the
first step in the metabolism of polycyclic aromatic hydrocar-
bons from cigarette smoke [5]. The activity of aryl hydrocar-
bon hydroxylase encoded by the CYP1A1 gene has been
observed in both normal and neoplastic human breastR460
bp = base pairs; CBCS = Carolina Breast Cancer Study; CI = confidence interval; CYP1A1 = cytochrome P4501A1; ETS = environmental tobacco 
smoke; ICR = interaction contrast ratio; OR = odds ratio; PCR = polymerase chain reaction; RFLP = restriction fragment length polymorphism.
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R461epithelium [6,7]. Some studies suggest that heterocyclic
amines are activated by CYP1A1 via N-hydroxylation in
breast tissue [8]. Four common polymorphisms of the
CYP1A1 gene have been identified: M1, a T → C substitu-
tion at nucleotide 3801, giving rise to a MspI restriction site
in the 3'-noncoding region [9]; M2, nucleotide 2455 A →
G, resulting in an amino acid change at codon 462 of iso-
leucine to valine within the heme-binding domain of exon 7
[10]; M3, nucleotide 3205 T → C, creating a MspI restric-
tion fragment length polymorphism (RFLP) in the 3'-non-
coding region [11]; and M4, nucleotide 2453 C → A,
resulting in an amino acid substitution at codon 461 of thre-
onine to asparagine [12].
The functional significance of variant CYP1A1 genotypes is
unclear. Studies of CYP1A1 in cultured human lym-
phocytes showed significantly elevated levels of inducible
enzyme activity among M2 genotypes compared with the
wild-type genotype [13-15]. Crofts and colleagues [15]
reported that M2 alleles appeared to be associated with
CYP1A1 inducibility at the level of transcription followed by
threefold elevation in aryl hydrocarbon hydroxylase enzyme
activity. The M1 allele was also reported more readily induc-
ible than the CYP1A1 wild-type allele [14,16,17].
Several epidemiologic studies evaluated the relationship
between cigarette smoking, CYP1A1 polymorphisms, and
breast cancer risk [18-22]. Some studies reported that M1
and M2 variants increase risk of breast cancer [18,21],
while other studies did not observe main effects for
CYP1A1 variants [19,21]. Joint effects of smoking and
CYP1A1 variants on breast cancer risk have been reported
in two studies [18,22].
In a population-based, case–control study of African-Amer-
ican and white women in North Carolina, we examined the
association of the CYP1A1 genotypes and cigarette smok-
ing and breast cancer. We hypothesized that women with
CYP1A1 variant alleles and high levels of smoking expo-
sure (longer duration, higher dose, earlier age at initiation)
as well as exposure to environmental tobacco smoke (ETS)
would be at increased risk for breast cancer.
Materials and methods
Study design and participants
The Carolina Breast Cancer Study (CBCS) is a population-
based, case–control study of breast cancer in African-
American and white women in North Carolina [23,24]. The
cases were women with a first diagnosis of invasive breast
cancer identified through a rapid ascertainment system
implemented in cooperation with the North Carolina Cen-
tral Cancer Registry. The coverage rate of the Central Can-
cer Registry for incident breast cancer cases was 97%
[23]. Controls were selected from lists provided by the
North Carolina Division of Motor Vehicles for women
younger than 65 years old, and from records of the US
Health Care Financing Administration for women 65–74
years of age. Coverage rates for the underlying North Caro-
lina population were 96% for the Division of Motor Vehicles
list and 93% for the Health Care Financing Administration
list [23].
The CBCS was conducted in two phases: phase 1 (1993–
1996) and phase 2 (1996–2001). The present analysis is
based upon phase 1 participants, where the response
rates were 76% for cases and 55% for controls. Detailed
methods have been reported previously [23]. Interview
data included reproductive history, lifestyle factors, a
detailed family history, medical history, and occupational
history. Approximately 98% of participants who were inter-
viewed agreed to give a 30 ml blood sample at the time of
interview. Informed consent to obtain genomic DNA from
the blood was sought using a form approved by the Institu-
tional Review Board of the University of North Carolina,
School of Medicine and in compliance with the Helsinki
Declaration. For the present study, we genotyped CYP1A1
on the first 688 breast cancer cases and 702 controls
enrolled in phase 1 of the CBCS. Due to financial con-
straints, we were unable to genotype all study participants.
The genotyped participants correspond to 80% of the 861
total cases and 89% of the 790 total controls enrolled in
phase 1 of the CBCS.
Laboratory methods
Genomic DNA was extracted from peripheral blood leuko-
cytes using an automated DNA extractor (Applied Biosys-
tems, Foster City, CA, USA) and was stored at 4°C. PCR-
RFLP assays were designed to detect each of the variant
CYP1A1 alleles. Several systematic nomenclatures for
CYP1A1 have been proposed [25]. Wild-type CYP1A1
has been referred to as CYP1A1*1 or CYP1A1*1A, M1 as
CYP1A1*2 or CYP1A1*2A, M2 as CYP1A1*2B (for the
combination of M1 + M2) or CYP1A1*2C (for M2 only), M3
as CYP1A1*3, and M4 as CYP1A1*4. To avoid confusion,
we have retained the M1–M4 designations, as recently
adopted by Bartsch and colleagues [25]. The variant alleles
M2 and M4 lose BsaI and BsrDI restricted sites at nucleo-
tides 4889 and 4887, respectively. An internal control for
the completeness of digestion was created by introducing
a restriction-enzyme site in the PCR primers designed for
genotyping of M2 and M4 alleles. The variant alleles M1
and M3 contain MspI restricted sites at nucleotides 6235
and 5639, respectively. These restricted sites do not exist
on the wild-type allele.
PCR primers used to determine M2 and M4 alleles include
the forward primer 5'-CTGTCTCCCTCTGGTTACAG-
GAAGC-3', which contains a BsrDI site, and the reverse
primer 5'-TTCCACCCGTTGCAGCAGGATAGCC-3',
which contains a BsaI site. PCR began with a 25 µl
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and reverse primers, 1.25 U Taq DNA polymerase (Perkin-
Elmer, Foster City, CA, USA) and 1 × PCR buffer (50 mM
KCl, 10 mM Tris–HCl [pH 9.0], 1.5 mM MgCl2, and 0.1%
Triton X-100). After samples were heated to 80°C, 50 µmol
each of dATP, dGTP, dCTP, and dTTP (Pharmacia, Piscat-
away, NJ, USA) were added. PCR was carried out in a ther-
mocycler 4800 (Perkin-Elmer Cetus, Norwalk, CT, USA).
Amplification conditions included 95°C for 5 min, 62°C for
2 min, and 72°C for 2 min for the first cycle; 95°C for 1 min,
62°C for 2 min, and 72°C for 2 min for the following 33
cycles; and 95°C for 1 min and 72°C for 10 min for the final
cycle.
PCR products of length 214 bp were produced after ampli-
fication and 4 µl PCR products were subjected to BsrDI
(for M2) or BsaI (for M4) digestion (New England Biolabs,
Beverly, MA, USA) at 37°C in a total volume of 13 µl. PCR
products from the wild-type allele was digested and sepa-
rated on a 15% polyacrylamide gel with bands of 149 bp
and 55 bp fragments. M2 or M4 variant alleles were undi-
gested at polymorphic sites, and appeared as a band of
206 bp on the electrophoresis. The fragment of 214 bp
represented incompletely digested PCR products, which
could be distinguished from the band for M2 or M4 variant
alleles on a 15% polyacrylamide gel.
PCR primers used to determine M1 and M3 alleles
included the forward primer 5'-GGCTGAGCAATCTGAC-
CCTA-3' and the reverse primer 5'-GGCCCCAACTACT-
CAGAGGCT-3'. Reaction components were the same as
for the PCR for genotyping of M2 and M4 alleles. Amplifi-
cation conditions included: 95°C for 5 min, 64°C for 2 min,
and 75°C for 2 min for the first cycle; 95°C for 1 min, 64°C
for 2 min, and 75°C for 2 min for the following 33 cycles;
and 95°C for 1 min and 72°C for 10 min for the final cycle.
PCR products of length 739 bp were produced and 8 µl
PCR products were subject to MspI/SphI digestion in a
total volume of 25 µl. After 15% polyacrylamide gel electro-
phoreses, the separated bands of size 408 bp and 362 bp
represented the wild-type and M1 alleles, respectively; and
the bands of size 331 bp and 226 bp were determined as
the wild-type and M3 alleles, respectively.
The introduced restriction-enzyme sites within the primers
were designed as an internal control in order to assess the
completeness of enzymatic digestion. Genotyping results
were determined by two independent readers. Readers
and laboratory personnel were blinded to the case–control
status and other participant characteristics. When inter-
preting the results, the two readers were unaware of each
other other's interpretations. All discrepancies in genotyp-
ing results between readers were then resolved through
group discussion, and agreement was achieved on all sam-
ples with discordant genotyping results. Repeat genotyp-
ing for 5% of samples (70 subjects) randomly selected
from study subjects was performed to evaluate reproduci-
bility. The results were 100% concordant for the repeat
samples. Positive controls were also used for genotyping at
each CYP1A1 locus.
Statistical analysis
Genotype frequencies were compared in cases versus
controls using a chi-square test. When cell sizes were less
than five, Fisher's exact test was used. In order to partially
address the potential for linkage disequilibrium among
CYP1A1 alleles, we cross-classified participants accord-
ing to combinations of wild-type and variant alleles at each
locus. Haplotypes (specific chromosomal combinations of
CYP1A1 alleles) cannot be identified directly using PCR-
RFLP techniques. For example, gel patterns cannot distin-
guish cis versus trans relationships for M1 and M3 alleles.
CYP1A1 haplotype frequencies were thus estimated using
the EH algorithm [26]. Haplotype frequencies in cases and
controls were compared using a likelihood ratio test, as
implemented in the EH algorithm.
Information concerning exposure to tobacco smoke was
obtained from inperson interviews. The reference date was
the date of diagnosis for cases and the date of selection for
controls. To calculate the odds ratios (ORs) for active
smoking, women who smoked fewer than 100 cigarettes in
their lifetime constituted the referent group (nonsmokers).
Women who never actively smoked but who had lived with
a smoker after the age of 18 years were classified as
exposed to ETS. The duration of active smoking was calcu-
lated by asking 'Keeping in mind that you may have stopped
and started several times, overall how many years did you
smoke regularly?' The dose of smoking was calculated in
packs per day (20 cigarettes to a pack).
The ORs for active smoking and the CYP1A1 genotype did
not differ when women with exposure to ETS were
excluded from the referent group. Thus, to increase sample
size, ORs for active smoking were calculated including
women with ETS exposure in the referent group. For analy-
ses of smoking and the CYP1A1 genotype on a multiplica-
tive scale, analyses of ETS were conducted among women
who never smoked themselves, using women exposed to
neither active smoking nor ETS as a referent group [24].
Smoking information was missing for 10 cases and for
seven controls.
The ORs and 95% confidence intervals (CIs) were used to
measure associations between CYP1A1 genotypes and
breast cancer and between smoking status and breast can-
cer, using unconditional logistic regression models. PROC
GENMOD of the software package SAS (version 8.1; SAS
Institute, Cary, NC, USA) was used to incorporate offsets
derived from sampling probabilities used to identify eligible
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R463participants. Covariates included age, race (white/African
American), age at menarche (≥ 12 years or < 12 years),
parity (nulliparous, 1 and ≥ 2), family history of breast can-
cer (yes/no), benign breast biopsy (yes/no), and alcohol
consumption (yes/no). ORs did not differ after adjusting for
additional covariates, so results are presented adjusting for
sampling fractions, age, and race (when appropriate).
Analyses of smoking effects according to CYP1A1 geno-
types were conducted using the categories smoking status
(current, former), duration, dose, time since cessation, and
age at initiation. These categories and cut points were cre-
ated in previous analyses that ignored the CYP1A1 geno-
type [24], and they represent aspects of smoking exposure
that showed the strongest associations with breast cancer
in the entire dataset. Stratified analyses were performed
based on menopausal status, since previous analyses
showed stronger effects for smoking in postmenopausal
compared with premenopausal women [24]. Women were
classified as postmenopausal if they had undergone natural
menopause, bilateral oophorectomy, or irradiation to the
ovaries. Natural menopause was defined as the cessation
of regular (or approximately monthly) menstrual cycles.
Women in the transition (perimenopausal) period were
classified as postmenopausal. For women aged 50 years or
older, postmenopausal status was assigned to those who
had not stopped cycling but were taking hormone replace-
ment therapy.
To assess interaction on a multiplicative scale, ORs for
smoking were estimated across strata of CYP1Al geno-
types, and separate logistic models with interaction terms
between smoking and the CYP1Al genotypes were ana-
lyzed. To estimate independent and joint effects of ciga-
rette smoking and the CYP1Al genotype on an additive
scale, indicator variables were created for each category of
joint exposure of smoking variable and the CYP1Al geno-
type (variant allele/variant allele or variant allele/wild-type
allele). Women with the homozygous wild-type allele geno-
types (wild-type allele/wild-type allele) and the lowest level
of exposure to smoking variable were used as a common
reference group.
Interaction contrast ratios (ICR) and CIs were calculated as
described by Hosmer and Lemeshow [27] for the joint
effects of the M1 locus and smoking. Data were too sparse
to calculate ICRs for the remaining CYP1A1 loci. The ICR
was calculated using the following formula [27]: ICR =
OR11 - OR10 - OR01 + 1, where OR11 is the odds ratio for
participants with smoking exposure and variant-containing
CYP1A1 genotype, OR10 is the odds ratio for the variant
CYP1A1 genotype among those unexposed to smoking,
and OR01 is the odds ratio for smoking exposure among
those with the nonvariant CYP1A1 genotype.
ICRs greater than zero imply greater than additive effects of
smoking and the CYP1A1 genotype (synergy), ICRs of
zero imply additive effects (no interaction on an additive
scale), and ICRs less than zero imply less than additive
effects (antagonism). The 95% CIs for ICRs that do not
contain zero can be interpreted as statistically significant at
an alpha level of 0.05.
Results
Characteristics of breast cancer cases and controls, and
ORs for breast cancer and smoking as well as other risk
factors, have been published previously for the CBCS [24].
Briefly, no association was observed between current
smoking and breast cancer. Smoking of 20 years or longer
duration and cessation of smoking within 3 years of the ref-
erence date among former smokers showed modest asso-
ciations with breast cancer [24]. These associations were
stronger among postmenopausal compared with premeno-
pausal women. The ORs for smoking were similar in Afri-
can-American and white women.
Genotype frequencies for CYP1A1 M1, M2, M3 and M4
are presented in Table 1. M1-containing genotypes were
found in both African-American and white women, and at a
slightly higher frequency among the African-American
women. M2-containing and M4-containing genotypes were
more common in white women, and M3-containing geno-
types more common in African-American women. Geno-
type frequencies for CYP1A1 variants in our study
population were similar to those in previous studies
[18,20,21]. The CYP1A1 haplotype frequencies were esti-
mated for the loci encoding M1 and M3 in African-Ameri-
can women, and those encoding M1, M2 and M4 in white
women. Haplotype frequencies did not differ between
cases and controls in African-American women (P = 0.9)
and in white women (P = 0.95). Among African-American
women, haplotype frequencies were wt + wt (67%), M1 +
wt (23%), wt + M3 (10%) and M1 + M3 (< 0.01%). Among
white women, haplotype frequencies were wt + wt + wt
(83%), M1 + wt + wt (8%), wt + wt + M4 (4%), M1 + M2
+ wt (4%), and the remaining combinations of alleles (total
of 1%).
The ORs for CYP1A1 genotypes and breast cancer are
presented in Table 2 for African-American and white
women. Although a slight positive association was
observed among African-American women for the M1/M1
genotype and breast cancer, and among white women for
the M2/M2 genotype and breast cancer, the results are not
statistically significant. The remaining ORs were close to
1.0, with the exception of an inverse association for M4
alleles in African-American women that was very imprecise
due to small numbers. The ORs for CYP1A1 genotypes in
premenopausal and postmenopausal women are pre-
sented in Table 3 and were also close to 1.0. ORs were
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history, alcohol, smoking, or other breast cancer risk factors
(data not shown).
We calculated the ORs for combined CYP1A1 alleles, but
the results were imprecise due to small numbers. Among
African-American women, using wild-type homozygotes for
the M1 and M3 loci as a referent group, the ORs were 0.8
(95% CI = 0.5–1.4) for wt/wt (M1 locus) + any M3 (M3
locus), 0.9 (95% CI = 0.6–1.3) for any M1 (M1 locus) + wt/
wt (M3 locus), and 1.4 (95% CI = 0.6–3.0) for any M1 (M1
locus) + any M3 (M3 locus). Among white women, using
wild-type homozygotes for the M1, M2 and M4 loci as a ref-
erent group, the ORs were close to 1.0 for all combinations
of M1, M2 and M4 alleles.
The ORs for smoking and breast cancer in relation to
CYP1A1 M1 genotypes are presented in Table 4. Among
current smokers, the ORs were close to 1.0 for women with
M1 (wt/M1 or M1/M1) as well as wild-type genotypes. ORs
for former smoking, for smoking for longer than 20 years,
for cessation of smoking within 10 years prior to the refer-
ence date, for initiation of smoking before age 18, and for
exposure to ETS were higher among women with M1 gen-
otypes compared with wild-type genotypes. The ORs were
elevated further among carriers of one or more copies of
the M1 allele for former smoking and for smoking cessation
within 10 years in postmenopausal women, and for initia-
tion of smoking prior to age 18 and for ETS exposure in pre-
menopausal women. The ORs for the number of cigarettes
per day did not show a dose–response relationship.
Table 1
Genotype frequencies for CYP1A1 among African-American and white participants in the Carolina Breast Cancer Study (1993–1996)
African-Americans Whites
Cases (n = 271) Controls (n = 285) Cases (n = 417) Controls (n = 417)
M1 locus
wt/wt 155 (59%) 165 (59%) 327 (79%) 325 (78%)
wt/M1 93 (35%) 102 (36%) 78 (19%) 83 (20%)
M1/M1 17 (6%) 13 (5%) 8 (2%) 7 (2%)
Missing 6 5 4 2
Chi-square test, P* 0.65 0.89
M2 locus
wt/wt 259 (96%) 274 (96%) 385 (92%) 378 (90%)
wt/M2 12 (4%) 11 (4%) 29 (7%) 37 (9%)
M2/M2 0 0 3 (1%) 2 (1%)
Missing 0 0 0 0
Fisher's exact test, P* 0.83 0.61
M3 locus
wt/wt 218 (82%) 227 (81%) 412 (99.8%) 413 (99.6%)
wt/M3 47 (18%) 47 (17%) 1 (0.2%) 1 (0.2%)
M3/M3 0 6 (2%) 0 1 (0.2%)
Missing 6 5 4 2
Fisher's exact test, P* 0.06 0.99
M4 locus
wt/wt 267 (98.5%) 278 (97.5%) 378 (90.7%) 377 (90%)
wt/M4 3 (1.1%) 7 (2.5%) 38 (9.1%) 40 (10%)
M4/M4 1 (0.4%) 0 1 (0.2%) 0
Missing 0 0 0 0
Fisher's exact test, P* 0.28 0.91
Data presented as n (%). wt, wild type. * Comparing cases and controls.
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American women, the ORs for smoking and breast cancer
according to M2 genotype are presented for white women
only in Table 5. ORs for ETS exposure are not calculated
for M2, M3 or M4 genotypes due to sparse data. ORs for
active smoking did not differ appreciably according to the
M2 genotype. Results stratified by menopausal status were
very imprecise due to small numbers, but suggested a
stronger effect of genotype in premenopausal women. In
premenopausal women, the ORs for smoking for longer
than 20 years were 3.6 (95% CI = 0.3–40.8) for women
with M2 genotypes and 1.3 (95% CI = 0.7–2.4) for wild-
type genotypes. The corresponding ORs for postmenopau-
sal women were 0.9 (95% CI = 0.2–4.0) and 1.3 (95% CI
= 0.8–2.0)
The ORs for smoking and breast cancer according to the
M3 genotype in African-American women only are pre-
sented in Table 6, due to the low frequency of the M3 allele
in white women. Cessation of smoking within 10 years was
more strongly associated with breast cancer in women with
M3 genotypes than with wild-type genotypes. ORs for
smoking for longer than 20 years and for initiation of smok-
ing before age 18 were higher in women with M3 geno-
types than with wild-type genotypes. The ORs for the
number of cigarettes smoked per day did not differ accord-
ing to M3 genotype. Results stratified on menopausal sta-
tus were very imprecise. In premenopausal women, the OR
for initiation of smoking before age 18 was 7.3 (95% CI =
0.7–73.0) for women with M3 genotypes and was 1.6
(95% CI = 0.7–3.5) for wild-type genotypes. In postmeno-
Table 2
Odds ratios (ORs) for breast cancer in relation to the CYP1A1 genotypes, in African-American and white women
Overall African Americans Whites
Cases Controls OR (95% CI)a Cases Controls OR (95% CI)b Cases Controls OR (95% CI)b
M1 locus
wt/wt 482 490 Reference 155 165 Reference 327 325 Reference
M1/wt 171 185 1.0 (0.7–1.2) 93 102 1.0 (0.7–1.4) 78 83 0.9 (0.7–1.3)
M1/M1 25 20 1.2 (0.7–2.3) 17 13 1.3 (0.6–2.8) 8 7 1.1 (0.4–3.2)
M1/wt or M1/M1 196 205 1.0 (0.8–1.2) 110 115 1.0 (0.7–1.4) 86 90 1.0 (0.7–1.3)
Missing 10 7 6 5 4 2
M2 locus
wt/wt 644 652 Reference 259 274 Reference 385 378 Reference
M2/wt 41 48 0.8 (0.5–1.3) 12 11 1.0 (0.4–2.4) 29 37 0.8 (0.5–1.3)
M2/M2 3 2 1.3 (0.2–7.7)c 0 0 nd 3 2 1.3 (0.2–8.2)c
M2/wt or M2/M2 44 50 0.9 (0.6–1.3) 12 11 1.0 (0.4–2.4) 32 39 0.8 (0.5–1.3)
Missing 0 0 0 0 0 0
M3 locus
wt/wt 630 640 Reference 218 227 Reference 412 413 Reference
M3/wt 48 48 1.1 (0.7–1.7) 47 47 1.1 (0.7–1.7) 1 1 0.7 (0.0–11.4)c
M3/M3 0 7 nd 0 6 nd 0 1 nd
M3/wt or M3/M3 48 55 0.9 (0.6–1.4) 47 53 1.0 (0.6–1.5) 1 2 0.4 (0.0–4.0)c
Missing 10 7 6 5 4 2
M4 locus
wt/wt 645 655 Reference 267 278 Reference 378 377 Reference
M4/wt 41 47 0.9 (0.6–1.4) 3 7 0.5 (0.1–1.8)c 38 40 1.0 (0.6–1.6)
M4/M4 2 0 nd 1 0 nd 1 0 nd
M4/wt or M4/M4 43 47 0.9 (0.6–1.4) 4 7 0.6 (0.2–2.0)c 39 40 1.0 (0.6–1.6)
Missing 0 0 0 0 0 0
CI, confidence interval; wt, wild type; nd, not determined. a Adjusted for age, race, and sampling fractions. b Adjusted for age and sampling 
fractions. c Imprecise estimate.
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was 3.0 (95% CI = 0.9–10.7) for women with M3 geno-
types and was 1.3 (95% CI = 0.7–2.5) for wild-type
genotypes.
The ORs for smoking and breast cancer according to the
M4 genotype in white women are presented in Table 7, due
to the lower frequency of the M4 allele in African-American
women. The ORs were imprecise due to the low frequency
of the M4 allele, and did not differ appreciably by M4 gen-
otype. A suggestion of an inverse association with long
duration of smoking was observed for women with M4 gen-
otypes while a weak positive association was observed for
wild-type genotypes.
Joint effects of smoking and the M1 genotype are pre-
sented on an additive scale in Table 8. An indication of
greater than additive joint effects was observed for M1 gen-
otypes and former smoking, number of cigarettes smoked,
duration of smoking, cessation of smoking within 10 years,
and initiation of smoking before age 18. The ICRs were
highest for early age at initiation of smoking in premenopau-
sal women, and for cessation of smoking with 10 years in
both premenopausal and postmenopausal women.
Table 3
Odds ratios (ORs) for breast cancer in relation to CYP1A1 genotypes, according to menopausal status (African-American and white 
women combined)
Premenopausal Postmenopausal
Cases (n = 352) Controls (n = 321) OR (95% CI)a Cases (n = 336) Controls (n = 381) OR (95% CI)a
M1 locus
wt/wt 242 221 Reference 240 269 Reference
M1/wt 88 87 1.0 (0.7–1.4) 83 98 0.9 (0.7–1.3)
M1/M1 15 11 1.2 (0.6–2.8) 10 9 1.2 (0.5–3.0)
M1/wt or M1/M1 103 98 1.0 (0.7–1.4) 93 107 1.0 (0.7–1.3)
Missing 7 2 3 5
M2 locus
wt/wt 329 294 Reference 315 358 Reference
M2/wt 21 25 0.7 (0.4–1.3) 20 23 1.0 (0.6–1.9)
M2/M2 2 2 0.9 (0.1–6.3)b 1 0 nd
M2/wt or M2/M2 23 27 0.7 (0.4–1.3) 21 23 1.1 (0.6–2.0)
Missing 0 0 0 0
M3 locus
wt/wt 327 296 Reference 303 344 Reference
M3/wt 18 20 0.9 (0.4–1.8) 30 28 1.2 (0.7–2.2)
M3/M3 0 3 nd 0 4 nd
M3/wt or M3/M3 18 23 0.8 (0.4–1.5) 30 32 1.0 (0.6–1.8)
Missing 7 2 3 5
M4 locus
wt/wt 325 301 Reference 320 354 Reference
M4/wt 27 20 1.3 (0.7–2.3) 14 27 0.6 (0.3–1.1)
M4/M4 0 0 nd 2 0 nd
M4/wt or M4/M4 27 20 1.3 (0.7–2.3) 16 27 0.7 (0.4–1.3)
Missing 0 0 0 0
CI, confidence interval; wt, wild type; nd, not determined. a Adjusted for age, race, and sampling fractions. b Imprecise estimate.
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smoking exposure and CYP1A1 M1 genotype were not
statistically significant.
ORs were calculated for smoking according to combined
genotypes at the M1 and M3 loci in African-American
women, and at the M1, M2 and M4 loci in white women.
Results were imprecise due to small numbers. In African-
American women, the ORs for former smoking were slightly
higher for women with any M1 + wt/wt M3 genotypes (OR
= 1.9, 95% CI = 0.9–3.8) and wt/wt M1 + any M3 geno-
types (OR = 2.0, 95% CI = 0.6–6.2) than for participants
with wt/wt M1 + wt/wt M3 genotypes (OR = 1.6, 95% CI
= 0.8–3.0). Data were too sparse to calculate ORs among
participants with combined any M1 and any M3 genotypes
or to evaluate the effects of dose and duration of smoking.
Among white women, the ORs for former smoking were
elevated among participants with any M1 + wt/wt M2 + wt/
wt M4 genotypes (OR = 3.3, 95% CI = 1.3–8.3), but not
wt/wt M1 + wt/wt M2 + any M4 genotypes (OR = 1.4,
95% CI = 0.4–5.3) or wt/wt M1 + wt/wt M2 + wt/wt M4
genotypes (OR = 1.0, 95% CI = 0.7–1.5). Data were too
sparse to calculate ORs for former smoking in women with
other combinations of M1, M2 and M4 genotypes.
Table 4
Odds ratios (ORs) for breast cancer and smoking in relation to the CYP1A1 genotype at the M1 locus, according to menopausal 
status (White and African-American women combined)
All participants Premenopausal Postmenopausal
M1 genotypea wt genotypeb M1 genotype wt genotype M1 genotype wt genotype
Cases/
controls
OR (95% CI)c Cases/
controls
OR (95% CI)c Cases/
controls
OR (95% CI)c Cases/
controls
OR (95% CI)c Cases/
controls
OR (95% CI)c Cases/
controls
OR (95% CI)c
Active smoking 
status
Never 96/115 Reference 252/256 Reference 46/47 Reference 132/120 Reference 50/68 Reference 120/136 Reference
Former 65/47 1.7 (1.1–2.8) 143/129 1.2 (0.9–1.6) 37/26 1.5 (0.8–2.9) 62/53 1.0 (0.7–1.6) 28/21 1.9 (1.0–3.8) 81/76 1.3 (0.9–1.9)
Current 35/43 1.1 (0.6–1.8) 87/105 0.8 (0.6–1.2) 20/25 0.8 (0.4–1.7) 48/48 0.9 (0.6–1.4) 15/18 1.2 (0.6–2.7) 39/57 0.8 (0.5–1.3)
Number of 
cigarettes 
smoked (pack/
day)
Never 96/115 Reference 252/256 Reference 46/47 Reference 132/120 Reference 50/58 Reference 120/136 Reference
≤ 1 71/64 1.4 (0.9–2.2) 159/159 1.0 (0.8–1.4) 43/38 1.2 (0.6–2.2) 76/70 1.0 (0.6–1.5) 28/26 1.6 (0.8–3.0) 83/89 1.1 (0.7–1.6)
>1 29/26 1.4 (0.8–2.7) 68/74 1.0 (0.7–1.4) 14/13 1.1 (0.5–2.7) 32/30 0.9 (0.5–1.7) 15/13 1.7 (0.7–4.0) 36/44 1.0 (0.6–1.6)
Duration of 
smoking
Never 96/115 Reference 252/256 Reference 46/47 Reference 132/120 Reference 50/58 Reference 120/136 Reference
≤ 20 years 51/57 1.0 (0.6–1.7) 119/127 0.9 (0.7–1.3) 37/39 1.0 (0.5–1.8) 80/77 0.9 (0.6–1.4) 14/18 1.1 (0.5–2.4) 39/50 0.9 (0.6–1.5)
> 20 years 49/33 2.1 (1.2–3.5) 110/106 1.2 (0.9–1.6) 20/12 1.9 (0.8–4.4) 30/23 1.2 (0.7–2.2) 29/21 2.1 (1.0–4.1) 80/83 1.2 (0.8–1.7)
Former smokers: 
time since 
cessation of 
smoking
Never 96/115 Reference 252/256 Reference 46/47 Reference 132/120 Reference 50/58 Reference 120/136 Reference
< 10 years 41/14 3.7 (1.9–7.3) 76/53 1.5 (1.0–2.2) 23/8 2.9 (1.2–7.3) 33/24 1.1 (0.6–2.1) 18/6 4.6 (1.7–12.5) 43/29 1.8 (1.0–3.0)
≥ 10 years 24/33 1.0 (0.5–1.7) 67/76 1.0 (0.7–1.4) 14/18 0.8 (0.4–2.0) 29/29 0.9 (0.5–1.7) 10/15 0.9 (0.4–2.3) 38/47 1.0 (0.6–1.6)
Age started of 
smoking
Never 96/115 Reference 252/256 Reference 46/47 Reference 132/120 Reference 50/58 Reference 120/136 Reference
<18 years 35/25 1.7 (0.9–3.0) 87/84 1.0 (0.7–1.5) 24/12 1.9 (0.8–4.3) 45/44 0.9 (0.5–1.4) 11/13 1.2 (0.5–3.0) 42/40 1.2 (0.8–2.1)
≥ 18 years 65/65 1.3 (0.9–2.1) 143/150 1.0 (0.8–1.4) 33/39 0.9 (0.5–1.7) 65/57 1.1 (0.7–1.7) 32/26 1.8 (0.9–3.4) 78/93 1.0 (0.7–1.5)
Exposure to ETS
Unexposed to 
active smoking 
or ETS after age 
18
36/48 Reference 95/84 Reference 20/29 Reference 56/51 Reference 16/19 Reference 39/33 Reference
ETS after age 18 60/67 1.4 (0.8–2.5) 156/172 0.9 (0.7–1.4) 26/18 2.5 (1.0–6.1) 76/69 1.2 (0.7–2.0) 34/49 0.7 (0.3–1.7) 80/103 0.7 (0.4–1.2)
CI, confidence interval; wt, wild type; ETS, environmental tobacco smoke. a M1/M1 and M1/wt genotypes. b wt/wt genotype. cAdjusted for age, race, and sampling fractions.
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We conducted a population-based, case–control study of
invasive breast cancer in relation to cigarette smoking and
CYP1A1 polymorphisms in African-American and white
women in North Carolina. ORs for all four CYP1A1 variants
(M1, M2, M3 and M4) were close to the null value in each
subgroup examined (African-American and white women,
premenopausal and postmenopausal women). Two previ-
ous studies reported positive associations between
CYP1A1 variants and breast cancer. Taioli and colleagues
[21] found a moderate to strong association for M1 geno-
types among African-American women. A weak positive
association for M2 genotypes among Caucasians was
reported by Ambrosone and colleagues [18]. Two other
studies, by Ishibe and colleagues [22] and by Bailey and
colleagues [20], did not find an association between
CYP1A1 variants and breast cancer. The ORs for CYP1A1
genotypes in the latter two studies were similar to those of
the CBCS (ignoring smoking). The previous studies
[18,20-22] were smaller than the CBCS.
Most previous studies of CYP1A1 polymorphisms and
breast cancer categorized smoking as ever or never, and
did not investigate the effects of dose, duration, age at ini-
tiation, time since cessation, or exposure to ETS. The study
by Ishibe and colleagues was the only one to evaluate the
interaction between former smoking and M1 genotype, and
the authors observed no difference in breast cancer risk for
former smoking according to the M1 genotype [22]. Our
results suggest that the CYP1A1 M1 genotype modifies
the association between cigarette smoking and breast can-
cer risk among former smokers. Joint effects of the M1 gen-
otype and former smoking were most evident among those
who quit within 10 years of the reference date. ORs for the
duration, age at initiation of smoking, and ETS exposure
were also stronger in women with M1 genotypes, espe-
cially postmenopausal women. Ambrosone and colleagues
[18] showed that the CYP1A1 M1 genotype was associ-
ated with an increased risk among lighter smokers, but the
analysis was based only upon pack-years and did not
address dose, duration, or age at initiation. We observed a
Table 5
Odds ratios (ORs) for breast cancer and smoking in relation to the CYP1A1 genotype at the M2 locus (white women only)
M2 genotypesa wt genotypeb
Cases/controls OR (95% CI)c Cases/controls OR (95% CI)c
Active smoking status
Never 15/15 Referent 186/191 Referent
Former 11/18 0.5 (0.2–1.6) 125/106 1.2 (0.9–1.7)
Current 6/6 0.9 (0.2–3.5) 74/81 0.9 (0.6–1.4)
Number of cigarettes (pack/day)
Never 15/15 Referent 186/191 Referent
≤ 1 10/11 0.8 (0.3–2.6) 126/114 1.1 (0.8–1.6)
> 1 7/13 0.5 (0.1–1.5) 71/72 1.0 (0.7–1.5)
Duration of smoking
Never 15/15 Referent 186/191 Referent
≤ 20 years 6/16 0.3 (0.1–1.0) 105/100 1.0 (0.7–1.4)
> 20 years 11/8 1.4 (0.4–4.8) 94/87 1.3 (0.9–1.8)
Former smokers: time since cessation of smoking
Never 15/15 Referent 186/191 Referent
< 10 years 10/7 1.3 (0.4–4.3) 63/44 1.4 (0.9–2.2)
≥ 10 years 1/11 0.1 (0.0–0.8) 62/62 1.1 (0.7–1.7)
Age started smoking
Never 15/15 Referent 186/191 Referent
< 18 years 6/8 0.5 (0.1–2.0) 72/67 1.0 (0.7–1.6)
≥ 18 years 11/16 0.7 (0.2–2.0) 127/120 1.1 (0.8–1.6)
CI, confidence interval; wt, wild type. a M2/M2 and M2/wt genotypes. b wt/wt genotype. cAdjusted for age and sampling fractions.
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started smoking at an early age (< 18 years), in contrast to
Ishibe and colleagues [22] who found no interaction
between M1 genotypes and age at initiation of smoking.
We did not observe strong modification of the ORs for
smoking according to M2 genotypes. Ishibe and col-
leagues [22] found that women with the M2 genotypes
showed a stronger association for early age at initiation of
smoking compared with women with wild-type genotypes.
The study by Bailey and colleagues [20] is the only one to
evaluate the effect of the M3 genotype on ORs for smoking
and breast cancer. In a study that included African-Ameri-
can women, the authors [20] did not observe modification
of the ORs for smoking by M3 genotypes, but smoking was
categorized as ever versus never. For African-American
women with M3 genotypes, we observed a stronger asso-
ciation for cessation of smoking within 10 years of the ref-
erence date, for smoking for longer than 20 years, and for
initiation of smoking before age 18. These OR estimates
are imprecise, and additional studies of M3 genotype and
breast cancer in African-American women are needed.
There are several limitations to our study. The participation
rate in controls was low (55%) and could have lead to
biased estimates of effect. In a previous publication [28],
we addressed the potential for selection bias using infor-
mation from partial interviews conducted on persons who
refused to participate in the CBCS. Eligible participants
who refused were similar to full participants for most breast
cancer risk factors [28], and the prevalence of smoking
among controls in the CBCS was similar to previous sur-
veys of the North Carolina population [24]. Participation in
the CBCS is unlikely to be related to the CYP1A1 geno-
type, and therefore any bias in ORs for the CYP1A1 geno-
type, smoking, or the joint effects of these exposures is
likely to be towards the null. Due to financial constraints, we
were only able to genotype 80% of phase 1 CBCS cases
and 89% of controls. ORs for smoking and other expo-
sures, as well as distributions of these variables, did not dif-
Table 6
Odds ratios (ORs) for breast cancer and smoking in relation to the CYP1A1 genotype at the M3 locus (African-American women only)
M3 genotypesa wt genotypeb
Cases/controls OR (95% CI)c Cases/controls OR (95% CI)c
Active smoking status
Never 24/32 Referent 124/134 Reference
Former 16/11 1.9 (0.7–4.8) 58/42 1.7 (1.1–2.7)
Current 7/10 0.9 (0.7–2.8) 36/51 0.8 (0.5–1.3)
Number of cigarettes (pack/day)
Never 24/32 Referent 124/134 Reference
≤ 1 18/16 1.5 (0.6–3.5) 79/82 1.2 (0.8–1.7)
> 1 5/5 1.2 (0.3–4.7) 14/11 1.6 (0.7–3.8)
Duration of smoking
Never 24/32 Referent 124/134 Reference
≤ 20 years 8/13 0.8 (0.3–2.2) 54/55 1.2 (0.7–1.8)
> 20 years 15/8 2.5 (0.9–7.1) 39/37 1.3 (0.8–2.2)
Former smokers: time since cessation of smoking
Never 24/32 Referent 124/134 Reference
< 10 years 13/4 4.2 (1.2–14.6) 32/13 3.1 (1.5–6.1)
≥ 10 years 3/7 0.5 (0.1–2.3) 26/29 1.1 (0.6–2.0)
Age started smoking
Never 24/32 Referent 124/134 Reference
< 18 years 12/6 2.4 (0.8–7.5) 33/29 1.3 (0.7–2.3)
≥ 18 years 11/15 1.0 (0.4–2.5) 61/64 1.2 (0.8–1.8)
CI, confidence interval; wt, wild type. a M3/M3 and M3/wt genotypes. b wt/wt genotype. cAdjusted for age and sampling fractions.
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information and those without (data not shown); the results
presented here are therefore likely to be representative of
the entire CBCS.
As in previous studies of CYP1A1, RFLP-based laboratory
assays do not identify the phase of specific chromosomal
combinations of alleles within the CYP1A1 locus (haplo-
types). We thus estimated haplotypes using statistical
methods, an indirect measurement. Based upon estimated
haplotypes, it appears that the effects of the M1 and M3
alleles can be estimated independently in African-American
women, since few participants (< 0.01%) appeared to
carry the M1 + M3 haplotype. Among white women, some
of the effects of M1 may be due to M2, since a small
number (4%) of participants carried the M1 + M2 haplo-
type. Some of the effects of M2 may be due to M4, and vice
versa, since the two loci are in close physical proximity. In
our study population, the majority of participants with M4
were wild-type at M2, and neither allele was associated
with breast cancer risk.
We addressed confounding by most known risk factors for
breast cancer, but confounding by unmeasured factors
cannot be ruled out. Misclassification of self-reported
smoking status is possible. However, it is unlikely that resid-
ual confounding or misclassification of smoking would be
differential by the CYP1A1 genotype. Information on ETS
exposure was limited to exposure at home without meas-
urements of workplace or leisure activity. Failure to fully
measure ETS and to remove women with such exposure
from the referent group would lead to underestimates
(rather than overestimates) of smoking effects.
An additional limitation to our study is the problem of multi-
ple comparisons. We estimated ORs for many aspects of
smoking in premenopausal and postmenopausal women,
and some or all of the observed associations could be due
to chance. We did not base our analysis upon P values and
thus did not adjust for multiple comparisons, but instead
compared magnitude of ORs across categories of smoking
exposure and genotype. Our results appear to be consist-
ent with some previous epidemiologic studies as well as
Table 7
Odds ratios (ORs) for breast cancer and smoking in relation to the CYP1A1 genotype at the M4 locus (white women only)
M4 genotypesa wt genotypeb
Cases/controls OR (95% CI)c Cases/controls OR (95% CI)c
Active smoking status
Never 24/16 Reference 177/190 Reference
Former 13/8 1.2 (0.4–3.6) 123/116 1.1 (0.8–1.6)
Current 2/16 0.1 (0.0–0.4) 78/71 1.2 (0.8–1.7)
Number of cigarettes (pack/day)
Never 24/16 Reference 177/190 Reference
≤ 1 8/14 0.4 (0.1–1.2) 128/111 1.2 (0.9–1.7)
> 1 7/10 0.5 (0.2–1.6) 71/75 1.0 (0.7–1.5)
Duration of smoking
Never 24/16 Reference 177/190 Reference
≤ 20 years 11/12 0.6 (0.2–1.8) 100/104 0.9 (0.6–1.3)
> 20 years 4/12 0.2 (0.1–0.9) 101/83 1.5 (1.0–2.1)
Former smokers: time since cessation of smoking
Never 24/16 Reference 177/190 Reference
< 10 years 6/3 1.4 (0.3–6.6) 67/48 1.4 (0.9–2.2)
≥ 10 years 7/5 1.0 (0.3–3.8) 56/68 0.9 (0.6–1.4)
Age started smoking
Never 24/16 Reference 177/190 Reference
< 18 years 7/9 0.5 (0.2–1.8) 71/66 1.1 (0.7–1.6)
≥ 18 years 8/15 0.4 (0.1–1.1) 130/121 1.2 (0.9–1.7)
CI, confidence interval; wt, wild type. a M4/M4 and M4/wt genotypes. b wt/wt genotype. cAdjusted for age, race, and sampling fractions.
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Odds ratios (ORs) for breast cancer according to cigarette smoking and the CYP1A1 genotype at the M1 locus, according to 
menopausal status (African-American and white women combined), additive scale and interaction contrast ratios
Genotype Overall Premenopausal Postmenopausal
Cases/
controls
OR
(95% CI)a
ICR
(95% CI)
Cases/
controls
OR
(95% CI)a
ICR
(95% CI)
Cases/
controls
OR
(95% CI)a
ICR
(95% CI)
Active smoking 
status
Never wt/wtb 252/256 Reference 132/120 Reference 120/136 Reference
Never M1 variantc 96/115 0.8 (0.6–1.2) 46/47 0.9 (0.5–1.4) 50/68 0.8 (0.5–1.3)
Former wt/wt 143/129 1.2 (0.9–1.6) 62/53 1.0 (0.7–1.6) 81/76 1.3 (0.9–1.9)
Former M1 variant 65/47 1.4 (0.9–2.2) +0.4
(-0.2, 1.1)
37/26 1.3 (0.7–2.2) +0.4
(-0.5, 1.2)
28/21 1.5 (0.8–2.9) +0.5
(-0.5, 1.5)
Current wt/wt 87/105 0.8 (0.6–1.2) 48/48 0.9 (0.5–1.4) 39/57 0.8 (0.5–1.3)
Current M1 variant 35/43 0.9 (0.5–1.4) 20/25 0.7 (0.4–1.4) 15/18 1.0 (0.5–2.1)
Number of 
cigarettes 
(pack/day)
Never wt/wtb 252/256 Reference 132/120 Reference 120/136 Reference
Never M1 variantc 96/115 0.8 (0.6–1.2) 46/47 0.9 (0.5–1.4) 50/68 0.8 (0.5–1.3)
≤ 1 wt/wt 159/159 1.0 (0.8–1.4) 76/70 1.0 (0.6–1.4) 83/89 1.1 (0.7–1.6)
≤ 1 M1 variant 71/64 1.2 (0.8–1.7) 43/38 1.0 (0.6–1.7) 28/26 1.3 (0.7–2.3)
> 1 wt/wt 68/74 1.0 (0.7–1.4) 32/30 0.9 (0.5–1.6) 36/44 1.0 (0.6–1.7)
> 1 M1 variant 29/26 1.2 (0.7–2.1) +0.4
(-0.4, 1.1)
14/13 1.0 (0.4–2.2) +0.1
(-0.9, 1.1)
15/13 1.4 (0.6–3.0) +0.6
(-0.6, 1.7)
Duration of 
smoking
Never wt/wtb 252/256 Reference 132/120 Reference 120/136 Reference
Never M1 variantc 96/115 0.8 (0.6–1.2) 46/47 0.9 (0.5–1.4) 50/68 0.8 (0.5–1.3)
≤ 20 years wt/wt 119/127 0.9 (0.7–1.2) 80/77 0.9 (0.6–1.3) 39/50 0.9 (0.6–1.5)
≤ 20 years M1 variant 51/57 0.9 (0.6–1.3) 37/39 0.8 (0.5–1.4) 14/18 0.9 (0.4–1.7)
> 20 years wt/wt 110/106 1.2 (0.9–1.6) 30/23 1.2 (0.7–2.2) 80/83 1.2 (0.8–1.7)
> 20 years M1 variant 49/33 1.7 (1.1–2.8) +0.7
(-0.2, 1.6)
20/12 1.5 (0.7–3.3) +0.5
(-0.7, 3.8)
29/21 1.7 (0.9–3.1) +0.7
(-1.4, 5.3)
Time since 
cessation
Never wt/wtb 252/256 Reference 132/120 Reference 120/136 Reference
Never M1 variantc 96/115 0.8 (0.6–1.2) 46/47 0.9 (0.5–1.4) 50/68 0.8 (0.5–1.3)
< 10 years wt/wt 76/53 1.5 (1.0–2.2) 33/24 1.1 (0.6–2.0) 43/29 1.8 (1.0–3.0)
< 10 years M1 variant 41/14 3.0 (1.6–5.7) +1.7
(-0.7, 3.8)
23/8 2.4 (1.0–5.7) +1.6
(-0.7, 3.8)
18/6 3.6 (1.4–9.4) +2.0
(-1.4, 5.3)
≥ 10 years wt/wt 67/76 1.0 (0.7–1.5) 29/29 0.9 (0.5–1.7) 38/47 1.0 (0.6–1.6)
≥ 10 years M1 variant 24/33 0.8 (0.4–1.3) 14/18 0.7(0.3–1.5) 10/15 0.7 (0.3–1.7)
Age started 
smoking
Never wt/wtb 252/256 Reference 132/120 Reference 120/136 Reference
Never M1 variantc 96/115 0.8 (0.6–1.2) 46/47 0.9 (0.5–1.4) 50/68 0.8 (0.5–1.3)
< 18 years wt/wt 87/84 1.0 (0.7–1.5) 45/44 0.8 (0.5–1.4) 42/40 1.3 (0.8–2.1)
< 18 years M1 variant 35/25 1.4 (0.8–2.4) +0.5
(-0.3, 1.4)
24/12 1.6 (0.8–3.4) +0.9
(-0.4, 2.2)
11/13 1.0 (0.4–2.4) -0.1
(-1.1, 1.0)
≥ 18 years wt/wt 143/150 1.0 (0.8–14) 65/57 1.0 (0.7–1.6) 78/93 1.0 (0.7–1.5)
≥ 18 years M1 variant 65/65 1.1 (0.7–1.6) 33/39 0.8 (0.5–1.4) 32/26 1.4 (0.8–2.6)
CI, confidence interval. a Adjusted for age, race, and sampling fractions. b wt = wild-type homozygote genotype. c M1 variant = M1/M1 or M1/wt genotypes.
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alleles. Although our study is the largest to date among Afri-
can-American women, many of the OR estimates were
imprecise, and none of the ICRs were statistically signifi-
cant. Additional studies with a larger sample size as well as
data pooling across studies are needed to determine
whether some or all of the ORs and interactions in our
study and previous studies may be due to chance.
Conclusions
Our results suggest that CYP1A1 M1-containing and M3-
containing genotypes increase the risk of breast cancer
associated with a long duration (> 20 years) of cigarette
smoking, but the effects of the CYP1A1 genotype appear
to be quite weak. Additional information on the functional
characteristics of CYP1A1 alleles is needed, especially
within breast tissue, to address the biologic plausibility of
our findings. Since CYP1A1 is involved in activation of
polycyclic aromatic hydrocarbons, our results lend support
to the hypothesis that polycyclic aromatic hydrocarbon
exposure is associated with increased risk of breast can-
cer. Polycyclic aromatic hydrocarbon–DNA adducts are
formed within breast tissue and have been associated with
increased breast cancer risk [29].
Future studies of smoking and breast cancer need to
address the role of a variety of genetic polymorphisms
involved in the metabolism of polycyclic aromatic hydrocar-
bons, heterocyclic amines and other compounds found in
tobacco smoke. Large studies and data pooling will be
required to disentangle the complex effects of smoking.
Such studies are important since smoking may represent a
modifiable risk factor for breast cancer.
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